FDA approves first HIV therapy once a month

 2021 (HealthDay News) - The first monthly admissions for treating adults with HIV were approved by the U. Food and Drug Administration Thursday. 

 "Currently, the standard of care for HIV patients includes ingestion of patients Daily pills to adequately treat their condition. This approval allows some patients to receive injections once a month instead of daily oral treatment, "said Dr. John Farley, director of the Infectious Disease Office at the FDA Center for Drug Evaluation and Research.

 "The availability of this treatment for some patients offers an alternative to treating this chronic condition," he added in an agency press release.

An expert said that the recordings are likely to be welcomed by HIV patients.

The recordings will improve quality of life "to only be treated once a month," Dr Steven Deeks, an HIV specialist at the University of California at San Francisco, told CBS News . "People don't want those daily reminders that they are infected with HIV. "

 Another expert agreed.

" Even people who took a pill once a day reported an improvement in their quality of life to switch to an injection, "said Dr. Judith Currier, HIV specialist at the University of California in Los Angeles, she advises CBS News. She is a consultant for ViiV Healthcare, the company behind long-term treatment, and wrote a comment on a study of the drug that was recently published in the New England Journal of Medicine.

Not just that, but Deeks added that "there is a huge unmet need" that the recordings may fulfill as some patients, including people with mental illness or drug problems, are struggling with daily medication consumption.

Cabenuva (cabotegravir and rilpivirine), which are considered two separate Admitted shots was admitted to HIV-positive patients on a stable antiretroviral regimen - are suppressed, have had no treatment failure in the past, and did not know or suspect resistance to cabotegravir or rilpivirine, the FDA said.

T The FDA also approved Vocabria (cabotegravir, tablet formulation), which was given in combination with Cabenuva for one month before starting treatment with Cabenuva oral edurant (rilpivirine) should be taken to ensure that the medication is well tolerated by patients before switching to the extended treatment. monthly injection.

FDA approval of Cabenuva is based on two randomized, open, controlled clinical trials that enrolled nearly 1,200 HIV-infected adults who had HIV suppression prior to initiating treatment with Cabenuva. 

 Patients in both trials continued to show HIV suppression at the end of each study, according to the FDA. 

 The most common side effects with Cabenuva were injection site reactions, fever, fatigue, headache, musculoskeletal pain, nausea, sleep disturbances, dizziness. and rash. A month later, CBS News reported. The company said it is "within the range" of what a combination of pills a day costs. What a patient pays depends on insurance, income, and other things. 
Previous Post Next Post

BovoTv 2021 inc